Advertisement

Psychopharmacology

, Volume 123, Issue 1, pp 55–63 | Cite as

Nicotine effects on adults with attention-deficit/hyperactivity disorder

  • E. D. Levin
  • C. K. Conners
  • E. Sparrow
  • S. C. Hinton
  • D. Erhardt
  • W. H. Meck
  • J. E. Rose
  • J. March
Original Investigation

Abstract

Several lines of evidence suggest that nicotine may be useful in treating the symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD). The current study was an acute, placebo-controlled double-blind experiment to determine whether nicotine might be useful as an alternative treatment of adults with ADHD symptomatology. Six smokers and 11 nonsmokers who were outpatient referrals for ADHD were diagnosed by DSM-IV criteria. Measures of treatment effect included the Clinical Global Impressions (CGI) scale, Hopkins' symptom check list (SCL-90-R), the Profile of Mood States (POMS), Conners' computerized Continuous Performance Test (CPT), the Stroop test, and an interval-timing task. The smokers underwent overnight deprivation from smoking and were given a 21 mg/day nicotine skin patch for 4.5 h during a morning session. The nonsmokers were given a 7 mg/day nicotine skin patch for 4.5 h during a morning session. Active and placebo patches were given in a counterbalanced order approximately 1 week apart. Nicotine caused a significant overall nicotine-induced improvement on the CGI. This effect was significant when only the nonsmokers were considered, which indicated that it was not due merely to withdrawal relief. Nicotine caused significantly increased vigor as measured by the POMS test. Nicotine caused an overall significant reduction in reaction time (RT) on the CPT, as well as, with the smokers, a significant reduction in another index of inattention, variability in reaction time over trial blocks. Nicotine improved accuracy of time estimation and lowered variability of time-estimation response curves. Because improvements occurred among nonsmokers, the nicotine effect appears not to be merely a relief of withdrawal symptoms. It is concluded that nicotine deserves further clincal trials with ADHD.

Key words

Nicotine Attention Deficit/Hyperactivity Disorder Attention Treatment Nicotine skin patches 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ahtee L, Kaakkola S (1978) Effect of mecamylamine on the fate of dopamine in striatal and mesolimbic areas of rat brain: Interaction with morphine and haloperidol. Br J Pharmacol 62:213–218Google Scholar
  2. Barkley R (1990) Attention deficit hyperactivity disorder: a handbook for diagnosis and treatment Guidford, New YorkGoogle Scholar
  3. Barkley RA (1995) Impaired delayed responding: a unified theory of attention deficit hyperactivity disorder. In: Routh DK (ed) Disruptive behavior disorders in childhood: essays Honoring Herbert C. Quay. Plenum, New york, pp 1–73Google Scholar
  4. Benowitz NL (1993) Nicotine replacement therapy: what has been accomplished—can we do better? Drugs 45:157–170Google Scholar
  5. Church R, Miller KD, Meck WH, Gibbon J (1991) Symmetrical and asymmetrical sources of variance in temporal generalization. Anim Learn Behav 19:207–214Google Scholar
  6. Clarke PBS, Hommer DW, Pert A, Skirboll LR (1985) Electrophysiological actions of nicotine on substantial nigra single units. Br J Pharmacol 85:827–835Google Scholar
  7. Clarke PBS, Pert A (1985) autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res 348:355–358Google Scholar
  8. Clarke PBS, Pert CB, Pert A (1984) Autoradiographic distribution of nicotine receptors in rat brain. Brain Res 323:390–395Google Scholar
  9. Cloninger CR, Przybeck TR, Svrakic DM (1991) The Tridimensional Personality Questionnaire: US normative data. Psychol Rep 69:1047–1057Google Scholar
  10. Conners CK (1994) The Continuous Performance Test (CPT): use as a diagnostic tool and measure of treatment outcome. Annal Convention of the American Psychological Association. Los Angeles, Calif.Google Scholar
  11. Conners CK (1995) The Continuous Performance Test. Multi-Helath Systems, TorontoGoogle Scholar
  12. Conners CK, March JS, Fiore C, Butcher T (1994) Information processing deficits in ADHD: effect of stimulus rate and methylphenidate. Annual Meeting of the American College of NeuropsychopharmacologyGoogle Scholar
  13. Derogatis LR (1983) SCL-90-R; administration scoring and procedures manual-II Clinical Psychometric Research., Towson, md.Google Scholar
  14. DSM-IV Task Force (1994) Diagnostic and statistical manual for mental disorders: DSM-IV. American Psychiatric Association, Washington, D.C.Google Scholar
  15. Fagerstrom KO, Schneider NG (1989) Measuring nicotine dependence; a review of the Fagerström tolerance questionnaire. J Behav Med 12:159–182Google Scholar
  16. Fagerström KO, Pomerleau O, Giordani B, Stelson F (1994) Nicotine may relieve symptoms of Parkinson's disease. Psychopharmacology 116:117–119Google Scholar
  17. Grenhoff J, Aston-Jones G, Svensson TH (1986) Nicotinic effects on the firing pattern of midbrain dopamine neurons. Acta Physiol Scand 128:151–158Google Scholar
  18. Haikala H, Ahtee L (1988) Antagonism of the nicotine-induced changes of the striatal dopamine metabolism in mice by mecamylamine and pempidine. Naunyn-Schmiedberg's Arch Pharmacol 338:169–173Google Scholar
  19. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62Google Scholar
  20. Hatsukami D, Fletcher L, Morgan S, Keenan R, Amble P (1989) The effects of varying cigarette deprivation duration on cognitive and performance tasks. J Subst Abuse 1:407–416Google Scholar
  21. Henningfield JE (1984) Behavioral pharmacology of cigarette smoking. Adv Behav Pharmacol 4:131–210Google Scholar
  22. Hughes JR (1989) Dependence potential and abuse liability of nicotine replacement therapies. Biomed Pharmacother 43:11–17Google Scholar
  23. Ikard FF, Green DE, Horn O (1969) A scale to differentiate between types of smoking as related to the management of affect. Int J Addict 4:649–659Google Scholar
  24. Imperato A, Mulas A, Di Chiara G (1986) Nicotine preferentially stimulates dopamine release in the limbic system of freely moving rats. Eur J Pharmacol 132:337–338Google Scholar
  25. Jarvik ME (1991) Beneficial effects of nicotine. Br J Addict 86:571–575Google Scholar
  26. Jones GMM, Sahakian BJ, Levy R, Warburton DM, Gray JA (1992) Effects of acute subcutaneous nicotine on attention, information processing and short-term memory in Alzheimer's disease. Psychopharmacology 108:485–494Google Scholar
  27. Levin ED (1992) Nicotinic systems and cognitive function. Psychopharmacology 108:417–431Google Scholar
  28. Levin ED, Rose JE (1995) Acute and chronic nicotinic interactions with dopamine systems and working memory performance. In: Lajtha A, Abood L (eds) Functional diversity of interacting receptors, New York Academy of Sciences, New York, pp 218–221Google Scholar
  29. Levin ED, Rosecrans J (1994) The promise of nicotinic-based therapeutic treatments. Drug Dev Res 31:1–2Google Scholar
  30. Levin ED, Karan L, Rosecrans J (1993) Nicotine: an addicitive drug with therapeutic potential. Med Chem Res 2:509–513Google Scholar
  31. McConville BJ, Fogelson MH, Norman AB, Klykylo WM, Manderschied PZ, Parker KW, Sanberg PR (1991) Nicotine potentiation of haloperidol in reducing tic frequency in Tourette's disorder. Am J Psychiatry 148:793–794Google Scholar
  32. McNair DM, Lorr M, Droppleman LF (1981) EdITs manual for the profile of mood states. Educational and Industrial Testing Service, San DiegoGoogle Scholar
  33. Meck WH, Church RM (1987) Cholinergic modulation of the content of temporal memory. Behav Neurosci 101:207–214Google Scholar
  34. Meru G, Yoon KP, Boi V, Gessa GL, Naes L, Westfall TC (1987) Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Eur J Pharmacol 141:395–399Google Scholar
  35. Newhouse PA, Sunderland T, Tariot PN, Blumhardt CL, Weingartner H, Mellow A, Murphy DL (1988) Intravenous nicotine in Alzheimer's disease: a pilot study. Psychopharmacology 95:171–175Google Scholar
  36. NIMH (1985) CGI (Clinical Global Impression) scale. Psychopharmacol Bull 21:839–843Google Scholar
  37. Palmer KJ, Buckley MM, Faulds D (1992) Transdermal nicotine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy as an aid to smoking cessation Drugs. 44:498–529Google Scholar
  38. Peeke SC, Peeke HVS (1984) Attention, memory, and cigarette smoking. Psychopharmacology 84:205–216Google Scholar
  39. Penney TB, Williams CL, Meck WH (1993) Developmental dyslexia and attentional processing in a temporal bisection task. 21st Annual Meeting of the International Society for Developmental Psychobiology. Alexandria, Va.Google Scholar
  40. Pickworth WB, Bunker EB, Henningfield JE (1994) Transdermal nicotine: reduction of smoking with minimal abuse liability. Psychopharmacology 115:9–14Google Scholar
  41. Pomerleau CS, Downey KK, Stelson FW, Pomerleau OF (1995a) Smoking and adult ADHD: a connection? J Addict Dis (in press)Google Scholar
  42. Pomerleau OF, Downey KK, Stelson FW, Pomerleau CS (1995b) Cigarette smoking in adult patients diagnosed with attention deficit hyperactivity disorder. J Subst Abuse(in press)Google Scholar
  43. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, Newcombe RG, Russell MAH, Feyerabend C, Thomas GAO, Sawe U (1994) Transdermal nicotine for active ulcerative colitis. N Engl J Med 330:811–815Google Scholar
  44. Sahakian BJ, Jones GMM (1991) The effects of nicotine on attention, information processing, and working memory in patients with dementia of the Alzheimer type. In: Adlkofer F, Thruau K (eds) Effects of nicotine on biological systems. Birkhauser Verlag, Basel, pp 623–230Google Scholar
  45. Schwartz RD (1986) Autoradiographic distribution of high affinity muscarinic and nicotinic cholinergic receptors labeled with [3H] acetylcholine in rat brain. Life Sci 38:2111–2119Google Scholar
  46. Stroop JR (1935) Studies of interference in serial verbal reactions. J Exp Psychol 18:643–661Google Scholar
  47. Warburton DM, Arnall C (1994) Improvements in performance without nicotine withdrawal. Psychopharmacology 115:539–542Google Scholar
  48. Warburton DM, Rusted JM, Fowler J (1992) A comparison of the attentional and consolidation hypotheses for the facilitation of memory by nicotine. Psychopharmacology 108:443–447Google Scholar
  49. Wearden JH, McShane B (1988) Interval production as an analogue of the peak procedure: Evidence for similarity of human and animal timing process. Q J Exp Psychol 40B:363–375Google Scholar
  50. Wender P (1995) Attention-deficit hyperactivity disorder in adults. Oxford University Press, New YorkGoogle Scholar
  51. Wender PH, Wood DR, Reimherr FW (1991) Pharmacological treatment of attention deficit disorder, residual type (ADD-RT) in adults. In: Greenhill LL, Osman BB (ed) Ritalin: theory and patient management. Mary Ann Liebert, New York, pp 25–33Google Scholar
  52. Wesnes K, Warburton DM (1983) Smoking, nicotine and human performance. Pharmacol Ther. 21:189–208Google Scholar
  53. Wesnes K, Warburton DM (1984a) The effects of cigarettes of varying yield on rapid information processing performance. Psychopharmacology 82:338–342Google Scholar
  54. Wesnes K, Warburton DM (1984b) Effects of scopolamine and nicotine on human rapid information information processing performance. Psychopharmacology 82:147–150Google Scholar
  55. Wesnes K, Warburton DM, Matz B (1983) Effects of nicotine on stimulus sensitivity and response bias in a visual vigilance task. Neuropsychobiology 9:41–44Google Scholar
  56. Westman E, Levin E, Rose J (1995) Nicotine as a therapeutic drug. NC Med J 56:2–5Google Scholar
  57. Williams JBW (1988) A structured interview guide for the Hamilton depression rating scale. Arch Gen Psychiatry 45:742–747Google Scholar
  58. Wonnacott S, Irons J, Rapier C, Thorne B, Lunt GG (1989) Presynaptic modulation of transmitter release by nicotinic receptors. In: Nordberg A, Fuxe K, Holmstedt B, Sundwall A (ed) Progress in brain research. Elsevier Science Publishers B.V., New York, pp 157–163Google Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • E. D. Levin
    • 1
  • C. K. Conners
    • 1
  • E. Sparrow
    • 1
  • S. C. Hinton
    • 1
  • D. Erhardt
    • 1
  • W. H. Meck
    • 1
  • J. E. Rose
    • 1
  • J. March
    • 1
  1. 1.Department of Psychiatry, Neurobehavioral Research Laboratory, Box #3412Duke University Medical CenterDurhamUSA

Personalised recommendations